Financial Data and Key Metrics Changes - The company reported full-year revenue of $185.7 million, exceeding guidance by approximately $700,000. Total Q4 revenue was $49.9 million, with an 18% year-over-year growth when excluding $14.3 million from high-volume CleanCap sales in Q4 2024 [6][19] - Adjusted EBITDA for Q4 was positive at $536,000, marking the first return to positive adjusted EBITDA in four quarters, an improvement of approximately $11 million sequentially from Q3 [7][21] - GAAP net loss before non-controlling interest for Q4 was $63 million, compared to a loss of $46.1 million in Q4 2024 [20] Business Line Data and Key Metrics Changes - TriLink generated $34.6 million in revenue for Q4, down 17% year-over-year, but base revenue grew 25% year-over-year when excluding the prior year's COVID CleanCap revenue [19][24] - Cygnus revenue was $15.3 million in Q4, up 4% year-over-year, driven by demand for HCP kits [19][25] - For the full year, TriLink revenue was $119.8 million, while Cygnus revenue increased 5% to $66 million [24][25] Market Data and Key Metrics Changes - Revenue by geography in Q4 was 55% from North America, 15% from EMEA, 21% from Asia Pacific (excluding China), 8% from China, and 1% from Latin and Central America [20] - The number of companies pursuing mRNA and guide RNA programs globally increased to 809, up from 643 a year ago, indicating sustained interest in RNA-based approaches [15] Company Strategy and Development Direction - The company aims to simplify operations, improve execution, and enhance customer engagement, positioning TriLink as a key player in the mRNA and gene-based therapeutic workflow [6][10] - Investments are prioritized in high-return opportunities across mRNA, cell and gene therapy, and biologic safety testing, with a robust pipeline of new product introductions planned for 2026 [12][14] - The company is focused on operational discipline and cost-saving measures, exceeding initial targets and positioning for revenue growth and positive cash flow in 2026 [8][26] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism for 2026, citing improved visibility and strong order volumes, particularly in GMP consumables and larger orders in Discovery [14][34] - The broader biotech environment appears to be stabilizing, with signs of recovery in biopharma funding, although smaller players remain cautious [14][16] - Customer feedback indicates a constructive FDA stance in areas like cell and gene therapy, which is expected to support ongoing program advancements [17] Other Important Information - The company completed the implementation of its remediation plan to address previously identified material weaknesses in internal controls [28] - The securities class action lawsuits against the company and certain former executives were dismissed in full [29] Q&A Session Summary Question: Visibility and order volume tracking for 2026 - Management noted that order volumes are materially higher than the previous year, particularly in GMP consumables and larger orders in Discovery, indicating confidence in forecasts for the year [33][34] Question: Demand factors for GMP consumables - Growth in GMP consumables is attributed to a broad set of customers rather than a single program, reflecting a diverse customer base [35][36] Question: Gross margin expansion details - Gross margin expansion of 1,200 basis points is driven by $65 million in annualized cost savings and improved product mix, particularly from GMP consumables [39] Question: Current mRNA pipeline trends - Management estimates about a third market share in the mRNA ecosystem, with growth expected as more programs transition from discovery to GMP [60][64] Question: COVID CleanCap revenue expectations - The company expects total COVID CleanCap revenue of $10 million-$20 million for 2026, all anticipated in the first half of the year [91][93]

Core Viewpoint - Standard BioTools Inc. reported its second quarter 2025 financial results, highlighting a strategic sale of SomaLogic to Illumina, which is expected to unlock up to $425 million in cash and enhance the company's financial position towards profitability by 2026 [3][6][10]. Financial Performance - Revenue for the second quarter of 2025 was $21.8 million, a decrease of 3% year-over-year, while total revenue for the first half of 2025 was $42 million, down 5% year-over-year [4][7]. - Consumables revenue increased by 18% year-over-year to $10.5 million in the second quarter, although total consumables revenue for the first half decreased by 3% to $18.6 million [7][21]. - Instruments revenue fell by 26% year-over-year to $5.2 million in the second quarter, with a slight decrease of 1% to $11.9 million for the first half [13][21]. - Services revenue was $6.1 million in the second quarter, down 8% year-over-year, and $11.5 million for the first half, down 11% year-over-year [13][21]. Gross Margin and Operating Expenses - Gross margin for the second quarter of 2025 was approximately 48.8%, compared to 46.1% in the same quarter of 2024, while non-GAAP gross margin was 54.1%, up from 48.6% [13][22]. - Operating expenses decreased by 11% year-over-year to $36.3 million in the second quarter, with non-GAAP operating expenses down by 1% to $27.9 million [13][23]. - The company achieved a net loss of $17.7 million in the second quarter, an improvement of 31% compared to a net loss of $25.4 million in the same quarter of 2024 [13][25]. Cash Position and Future Outlook - As of June 30, 2025, the company had $239.7 million in cash and cash equivalents, with expectations to reach at least $550 million upon closing the transaction with Illumina [6][19]. - The company is targeting adjusted EBITDA break-even in 2026, supported by a strong balance sheet and a lean operating model [3][6]. Strategic Developments - The sale of SomaLogic is seen as a pivotal milestone for the company, allowing for strategic capital deployment into high-quality assets to drive growth and long-term shareholder value [3][6]. - The company anticipates a high single-digit million decline in Americas academic revenue due to NIH funding pressures, impacting continuing operations more significantly [9]. Revenue Outlook - For fiscal year 2025, the company expects combined revenue in the range of $165 million to $175 million, with revenue from continuing operations projected between $78 million and $83 million [8].